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Abstract
Background: A major pathological hallmark of AD is the deposition of insoluble extracellular b-amyloid (Ab) plaques. There
are compelling data suggesting that Ab aggregation is catalysed by reaction with the metals zinc and copper.
Methodology/Principal Findings: We now report that the major human-expressed metallothionein (MT) subtype, MT-2A, is
capable of preventing the in vitro copper-mediated aggregation of Ab1–40 and Ab1–42. This action of MT-2A appears to
involve a metal-swap between Zn7MT-2A and Cu(II)-Ab, since neither Cu10MT-2A or carboxymethylated MT-2A blocked
Cu(II)-Ab aggregation. Furthermore, Zn7MT-2A blocked Cu(II)-Ab induced changes in ionic homeostasis and subsequent
neurotoxicity of cultured cortical neurons.
Conclusions/Significance: These results indicate that MTs of the type represented by MT-2A are capable of protecting
against Ab aggregation and toxicity. Given the recent interest in metal-chelation therapies for AD that remove metal from
Ab leaving a metal-free Ab that can readily bind metals again, we believe that MT-2A might represent a different therapeutic
approach as the metal exchange between MT and Ab leaves the Ab in a Zn-bound, relatively inert form.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia
within the ageing population. AD accounts for between 50% and
60% of dementia cases [1]. The pathological hallmarks of the
disease include extracellular b-amyloid (Ab) plaques, intracellular
neurofibrillary tangles and dystrophic neurites [2]. All of these
hallmarks arise from the abnormal and unregulated overproduc-
tion of insoluble proteinaceous structures. These proteinaceous
structures are responsible for the disruption to normal cellular
functioning ultimately leading to cell death.
The main constituents of Ab plaques are the 40- and 42-mer
peptides, Ab1–40 and Ab1–42 [3], which associate to form abnormal
extracellular deposits of fibrils and amorphous aggregates [4]. Ab
is derived from the b-amyloid precursor peptide (APP), which is a
normal protein [5,6] that is produced by neuronal and non-
neuronal cells [7,8]. APP is processed by a combination of a-, b-,
and/or c- secretases to form numerous protein products. The
plaque-forming Ab1–42 and Ab1–40 arise from the uncommon b-
and c-secretase cleavage of the APP.
The mechanisms underlying the aggregation of Ab have been
the subject of intense investigation. There is compelling data to
suggest that the aggregation of Ab is catalysed by reaction with the
metals zinc and copper. Cu-mediated aggregation of Ab leads to
the formation of copper-bound, SDS-insoluble Ab aggregates, that
are neurotoxic due to the ability of Ab-bound copper to undergo
redox reactions at the cell membrane to generate reactive oxygen
species [9,10]. Of note, Ab plaques deposited in the AD brain are
found to be enriched with metals, and in particular copper
[11,12].
Metallothioneins (MTs) are the major endogenous zinc- and
copper- binding protein within the brain. The MT-1/2 isoforms
(exemplified by the highly expressed member, MT-2A) are
characterised as highly neuroprotective proteins essential for brain
repair [13–15]. The metal-binding properties of MT-1/2 have
been well investigated, and it is recognised that these proteins are
capable of binding 7 divalent (Zn
2+) and up to 12 monovalent
(Cu
+) metal ions in vivo through two distinct metal-thiolate clusters,
termed the a- and b- domains [16]. The importance of MT in
maintaining metal homeostasis is clearly demonstrated in studies
involving exposure to heavy metals (either by diet or environment)
in MT-1/2 knockout mice, which leads to metal toxicity, while
MT-1/2 overexpressing mice are relatively protected from heavy
metal toxicity [see review, 17]. MTs also have important roles in
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of Menkes disease (a copper efflux disease) with MT-1/2 knockout
mice, which results in embryonic lethality [18].
Given the strong metal-binding properties of MT, we predict
that these proteins may be involved in regulating the metal-
binding and subsequent aggregation of Ab. Indeed, there is
substantial literature supporting a role for MTs in the pathophys-
iology of AD. These proteins are expressed by astrocytes, and their
expression is significantly upregulated in regions of Ab plaque
pathology in the pre-clinical [19] and clinical AD brain [20,21], as
well as in the brains of transgenic AD mice [22]. Notably, Meloni
et al [23] recently reported that the Zn(II)-MT-3 isoform is
capable of exchanging metals with Cu(II)-Ab to prevent the
formation of SDS-insoluble Cu(II)-Ab aggregates. The goal of this
study is to evaluate whether MT-2A, via its zinc- and copper-
binding properties, also represents an endogenous protective
mechanism against Ab aggregation and toxicity.
Results
MT-2A prevents copper-mediated formation of SDS-
insoluble Ab aggregates
To stimulate Ab aggregation, 25mMo fA b1–40 was mixed with
an equimolar concentration of copper and 200mM ascorbate, and
shaken at 300rpm for three days at 37uC. The resultant protein
aggregates were collected by ultracentrifugation, resuspended in
SDS-PAGE loading buffer and electrophoresed. Under these
conditions, no Ab1–40 was visualised on SDS-PAGE (Figure 1A),
as a consequence of the formation of copper-bound SDS-insoluble
aggregates (IA). In contrast, in the presence of Zn7MT-2A at
the range of 2.5–25mM, Ab1–40 formed aggregates (SA)(Figure 1B),
which dissolved in SDS and resolved as a single band on SDS-
PAGE of approximately 3–4kDa representing monomeric Ab1–40
(Figure 1A). As shown recently by Meloni et al [23] the struc-
turally related metallothionein isoform Zn7MT-3 was also capable
Figure 1. 25mMA b1–40, in the presence of 25mM copper and 200mM ascorbate, was incubated at 37uC for three days with shaking at
300rpm. This resulted in the formation of SDS-insoluble Ab aggregates (IA), which were not visualised on SDS-PAGE (A). The presence of Zn7-MT2A
(5–25mM) prevented formation of SDS-insoluble Ab aggregates (A). Instead, SDS-soluble aggregates (SA) were formed, that were resolved as a single
protein band of approximately 3–4kDa size, representing monomeric Ab1–40 peptide (A). A range of different MT forms were tested for the ability to
promote formation of SDS-soluble aggregates (SA)(B). Zn7MT-2A promoted formation of SDS-SA, and Zn7MT-3 had a similar effect but at 10-fold
higher concentration (B). The ability of MT-2A to prevent formation of SDS-IA was linked to metal-binding properties, as different metallated forms of
MT-2A had different effects upon Ab aggregation (B). When Cu-Ab1–40 or Cu-Ab1–42 aggregates were generated by three days of incubation, and
then incubated with shaking in the presence or absence of 25mMZ n 7MT-2A for up to three days, this was unable de-aggregate either Cu-Ab1–40 or
Cu-Ab1–42 pre-formed aggregates (C).
doi:10.1371/journal.pone.0012030.g001
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but required a 10-fold higher concentration than Zn7MT-2A
(Figure 1B). We also investigated whether Zn7MT-2A can
prevent the Cu-mediated aggregation of Ab1–42. Under the same
experimental conditions, 25mMZ n 7MT2A was able to completely
prevent Cu-Ab1–42 forming SDS-insoluble aggregates (results not
shown).
We also investigated whether MT-2A can de-aggregate pre-
formed Cu-Ab aggregates. Cu-Ab1–40 and Cu-Ab1–42 aggregates
were produced as described above (three day incubation), after
which time 25mMo fZ n 7MT-2A was added. However, incubation
with Zn7MT-2A for up to three days was unable to de-aggregate
either Cu-Ab1–40 or Cu-Ab1–42 pre-formed aggregates (Figure 1C).
To establish whether the metallation state of MT is respon-
sible for the ability of MT-2A to prevent aggregation of Ab1–40
into SDS-IA, several different metallated forms of MT-2A were
used. We found that Cu10MT-2A was not able to prevent the
formation of SDS-insoluble Ab1–40 aggregates (Figure 1). Further-
more, chemical modification of MT-2A to block metal binding, by
means of carboxymethylation of cysteine residues (CaMeMT-2A)
abolished the ability of MT-2A to prevent formation of insoluble
Ab1–40 aggregates (Figure 1). Finally, metal free (apo) MT-2A was
also unable to prevent copper-mediated formation of insoluble
Ab1–40. Based upon these observations, we predict that the zinc
bound to MT is required for the ability of MT to block copper-
mediated Ab1–40 aggregation.
Evidence that Zn7MT-2A prevents copper-mediated Ab
aggregation via metal exchange
One possible explanation for our observations is that there is a
metal exchange of copper and zinc between Zn7MT-2A and
Cu(II)Ab with the subsequent formation of Zn-bound Ab
aggregates and soluble Cu-bound MT. To test this hypothesis,
the amount of copper and zinc present in the aggregated Ab
samples was determined using inductively coupled plasma mass
spectrometry (ICP-MS). When Ab1–40 was aggregated for three
days in the presence of copper and ascorbate, the amount of
copper/zinc detected within the pellet fraction following ultra-
centrifugation was 89.2/27.1ng (Table 1). However, when Ab1–40
was aggregated in the presence of Zn7MT-2A, the amount of
copper present in the pellet fraction was significantly reduced to
47.5ng (approximately 53% decrease), while there was a
concomitant increase in zinc to 81.4ng (Table 1). There was no
change in copper/zinc levels however when CaMeMT-2A was
used (Table 1). This provides further evidence that a copper-zinc
exchange has occurred between Cu(II)-Ab and Zn7MT-2A. We
therefore predict that the action of MT-2A to prevent the
formation of insoluble Ab aggregates is due to metal exchange of
copper and zinc between Zn7MT-2A and Cu(II)Ab with the
subsequent formation of Zn-bound Ab which only forms soluble
protein aggregates.
Comparative measurement of the relative Cu(I)-binding
affinity of MT-2A with MT-3
An explanation for the different abilities of MT-2A and MT-3
to alter Cu(II)-Ab aggregation might lie in different copper-
binding properties of MT-2A and MT-3. Formal thermodynamic
analysis indicated that MT-3 has only slightly lower apparent
Cu(I)-binding affinity (KCu=0.4760.01 fM) (Figure 2A) as
compared with that which we have recently reported for MT-
2A (KCu=0.4160.02 fM) [24]. However, differences were
observed in the composition and affinities of individual copper-
thiolate clusters of MT-2 and MT-3. In ESI-MS studies in the
presence of 10mM DTT, we observed that copper was bound to
MT-3 in a mixture of major Cu12MT-3 and minor Cu10MT-3
forms (Figure 2B), while we have recently reported that MT-2A is
predominantly found in Cu10MT-2A form [24]. Addition of the
high affinity Cu(I)-binding chelator DETC at 0.5 mM concentra-
tion was sufficient to convert Cu12MT-3 to a predominant
Cu6MT-3 form, which could be further demetallated to apo-MT-3
at 3 mM DETC (Figure 2B). These observations indicate that
MT-3 binds copper in two distinct hexacopper clusters exposing
different Cu(I)-binding affinities. Conversely however, Cu10MT-
2A was stable at up to 1.0 mM DETC, and that 1.5mM DETC
was required to partially demetallate Cu10MT-2A to Cu6MT-2A
[24]. This suggests that tetracopper-thiolate cluster in Cu10MT-2A
has higher Cu(I)-binding affinity than low-affinity hexacopper-
thiolate cluster in Cu12MT-3, and may account for the greater
ability of MT-2A to prevent Cu(II)-Ab aggregation compared to
MT-3. We predict from the amino acid composition of MT-2A
and MT-3 that due to their high sequence homology that the N-
terminal b-domains will share similar metal-binding properties
(Figure 2C), most likely corresponding to the hexacopper-thiolate
cluster that is demetallated by treatment with 3mM DETC.
Subsequently, the C-terminal a-domain is likely to represent the
metal thiolate cluster that differs between the two isoforms and
which may contribute to the different copper-binding properties of
MT-2A and MT-3. To test this hypothesis we switched the
domains between isoforms to form chimeric recombinant MT-
3b2a and MT-2b3a proteins (note the the beta-domains of each
chimera are at the N-terminus, which is the same as native MTs).
Indeed, Zn7MT-3b2a was capable of preventing copper mediated
Ab aggregation to a similar degree as Zn7MT-2A, while the
Zn7MT-2b3a chimeric protein had a similar activity to Zn7MT-3
(Figure 2D).
MT-2A protects against Ab toxicity in cultured cortical
neurons
It has been reported previously that Cu(II)-Ab1–40 but not Zn(II)-
Ab1–40 is toxic to cultured neurons [12,25]. The combination of equi-
molar concentrations of Ab1–40 and Cu(II) ions results in all free
copper becoming rapidly bound to Ab1–40 to form Cu(II)-Ab1–40
[23]. We maintained rat cortical neurons for three days invitro (3DIV)
followed by treatment with 40mM Cu(II)-Ab1–40 and 300mM
ascorbate. After 24 hours, this treatment resulted in about an 80%
reduction in cell viability, as measured using an alamarBlueH cell
viability assay (Figure 3A). In parallel experiments we performed
direct cell counts to validate the alamarBlueH data, and observed a
Table 1. 25mMA b1–40 was mixed with 25mM copper and
200mM ascorbate (rapidly forming Cu(II)-Ab), and incubated
with shaking at 37uC for 72 hours, resulting in the formation
of aggregated Ab1–40.
Reaction Copper (ng) Zinc (ng)
40mM Cu(II)-Ab1–40 89.2 27.1
40mM Cu(II)-Ab1–40+25mM Zn7MT-2A 47.5* 81.4*
40mM Cu(II)-Ab1–40+25mM CaMeMT-2A 87.9 27
Pellets containing Ab1–40 were collected by ultracentrifugation, and the content of
copper and zinc in the pellet samples was measured by ICP-MS. All samples were
performed intriplicate,and theaveragepresented.Cu(II)-Ab1–40aggregationin the
presence of Zn7MT-2A resulted in a significant reduction in the amount of copper
(and increase in zinc) present in the aggregated Ab1–40 pellet in comparison to Cu-
(II)-Ab1–40 aggregated in the absence of MT-2A (p,0.05, t-test).
doi:10.1371/journal.pone.0012030.t001
MT Blocks Ab Aggregation
PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12030comparable degree of neurotoxicity in the presence of 40mM Cu(II)-
Ab1–40 (Figure S1). We found that Zn7MT-2A blocked Ab-induced
toxicity in a dose dependent manner (5–20mM range), with almost
complete protection at a concentration of 20mMZ n 7MT-2A
(Figure 3A). Furthermore, 20mMo fZ n 7MT-2A was far more
effective in protecting against Cu(II)-Ab neurotoxicity than 20mM
Zn7MT-3 (Figure 3A). Immunolabelling of neurons for the
cytoskeletal protein tau demonstrated that Zn7MT-2A protected
against Cu(II)-Ab induced neuronal degeneration (Figure 3B–D).
Treatment with ascorbate or Ab1–40 alone had no effect upon
viability (results not shown). Note that addition of MT-3 to neuronal
cultures can have powerful neurotoxic effects in its own right, if
applied in the presence of a brain derived extract or serum [26,27],
neither of which are present here. In contrast, in the absence of these
agents, MT-3 alone has no discernible neurotoxic effect.
To further investigate whether it is Cu(II)-Ab and not free copper
that is responsible for neurotoxicity, we fractionated a 40mM Cu(II)-
AbsolutiononaPDMidiTrap
TMG-25columnanddeterminedthe
protein (A280) and metal (ICP-MS) content of each fraction. Only
thosefractionscontainingpeptidealsocontainedcopper(Figure4A),
indicating that the Cu(II)-Ab solution did not contain any free
copper ions. The neurotoxicity of all fractions was subsequently
tested, and only those containing Cu(II)-Ab exhibited neurotoxic
activity (Figure 4B), demonstrating that Cu(II)-Ab is responsible for
the neurotoxicity that we have observed in our experiments.
To investigate whether MT-2A acts protectively via the zinc-
copper metal exchangebetweenZn7MT-2AandCu(II)-Abdescribed
above, Cu10MT-2A was used in the place of Zn7MT-2A, which
resulted in no neuroprotection against Cu(II)-Ab (Figure 5A). This
suggests that the metal exchange between MT-2A and Cu(II)-Ab is
required for neuroprotection. Notably, Cu10MT-2A alone was not
toxic to neurons (Figure 5A), confirming that when copper is bound
to MT it is unable to produce ROS. In parallel experiments, we
foundthatZn7MT-2Awasonlyabletomildlyblocktheneurotoxicity
of H2O2 when applied to cultured neurons (Figure 5B). The amount
of H2O2 directly applied to the neurons was physiologically relevant
as Huang and colleagues [28] found that 10mMA b1–40 or Ab1–42
may generate up to 25mMH 2O2 in 1 hour in the presence of
substoichiometric amounts of Cu(II), depending on the oxygen
tension. Since H2O2 is the direct ROS product of the interaction of
Figure 2. Using ESI-MS, we determined that the Cu(I)-binding affinity of MT-3 (KCu) is equal to 0.47±0.01 fM)(A). To investigate the
binding affinities of the individual copper-thiolate clusters of MT-3, we exposed Cu12MT-3 to the high affinity Cu(I)-binding chelator DETC (B). At
0.5 mM concentration DETC, Cu12MT-3 converted to a predominant Cu6MT-3 form, which could be further demetallated to apo-MT-3 at 3 mM DETC
(B). Human MT-3 shares approximately 60% amino acid sequence homology with human MT-2A (C). Conserved cysteines are highlighted in yellow,
and amino acid insertions indicated in purple. Zn7MT-3b2a was able to prevent formation of SDS-insoluble Ab1–40 aggregates (IA), while Zn7MT-2b3a
could only prevent insoluble aggregate formation at a concentration of 25mM (D).
doi:10.1371/journal.pone.0012030.g002
MT Blocks Ab Aggregation
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Zn7MT-2A is primarily upstream of ROS production. This is
consistent with our results suggesting that Zn7MT-2A acts via a metal
swap with Cu(II)-Ab to prevent ROS formation.
To further confirm that Zn7MT-2A is blocking the detrimental
effects of oxidative stress induced by Cu(II)-Ab, we have measured
changes in ionic homeostasis of neurons in response to Cu(II)-Ab
using a microelectrode ion flux measuring (MIFE) technique.
The MIFE technique allows direct measurement in changes in
K
+ and Ca
2+ fluxes in response to Cu(II)-Ab. Treatment with
Cu(II)Ab1–40 (in the presence of ascorbate) induced a rapid efflux of
K
+ out of neurons, peaking at 4.260.65 min after Cu(II)-Ab
application with K
+ outflow continuing over a period of
20 minutes (Figure 6A). The treatment also led to a moderate
influx of Ca
2+, peaking at 6.4561.35 min after the Cu(II)-Ab
application (indicated by crossing zero line) with Ca
2+ uptake
continuing over the experimental period (Figure 6C). Treatment
with Zn7MT-2A completely blocked Cu(II)-Ab induced changes in
K
+ and Ca
2+ fluxes, at a concentration of .5mM (Figure 6B, D).
Individual treatments with either Ab1–40 or Zn7MT-2A alone (in
the presence of ascorbate) had no effect upon any of the ions
measured (results not shown).
Discussion
The major findings of this study are that the major human-
expressed subtype of metallothionein, MT-2A, is capable of
preventing the formation of the toxic Cu-mediated aggregates of
Ab1–40 and Ab1–42. This action of MT-2A appears to involve a
metal-swap between Zn7MT-2A and Cu(II)-Ab since neither
Cu10MT-2A or carboxymethylated MT-2A blocked Cu(II)-Ab
aggregation. Furthermore, Zn7MT-2A blocked Cu(II)-Ab1–40
induced neurotoxicity of cultured cortical neurons. We propose
that there is therapeutic potential in a MT-2A based approach to
reducing Ab deposition in AD.
ItiswellestablishedthatMT-1/2expressioniselevatedinresponse
to almost all forms of stress to the brain, including traumatic-,
ischaemic or chemical- brain injury [25,29,30], or in neurodegen-
erative conditions such as ALS or EAE (an experimental animal
model of multiple sclerosis). The common consensus is that MT-1/2
act neuroprotectively, via intracellular functions such as metal
detoxification and quenching of oxidative free radicals. More
recently, it has been demonstrated that MT-1/2 can be actively
secreted by astrocytes under certain pathophysiological conditions
[15], and subsequently act from an extracellular location directly
upon neurons to activate intracellular neuroprotective pathways
[15,31,32]. However, an unexpected and specific protective function
of MT in the AD brain has recently been proposed by Meloni and
colleagues [23], who have found that Zn7MT-3 is able to prevent
copper-mediated aggregation of Ab in vitro, and protect a neuronal
cell line from soluble Ab1–40 toxicity. There is some controversy over
the level of expression of MT-3 in the AD brain, although it appears
that expression is downregulated in AD. Furthermore, the expression
of MT-3 is not induced by metals or oxidative stress, and this protein
displays neurotoxic actions under someconditions [14,26], suggesting
that it is unlikely that this protein contributes greatly to a protective
mechanism against Ab aggregation and toxicity. The MT-1/2
isoforms however (as exemplified by MT-2A) are broadly expressed
within the adult brain, and greatly elevated levels of expression of
these proteins have been noted in the AD brain [20–22].
Figure 3. Treatment of 3DIV rat cortical neuron cultures with 40mMA b1–40 (in the presence of 40mM CuCl2 and 300mM ascorbate)
resulted in approximately 80% reduction in neuronal viability 24 hours after treatment (A). 20mMo fZ n 7MT-2A was far more effective in
protecting against Ab1–40 neurotoxicity than 20mMZ n 7MT-3 (A). Immunolabelling for tau demonstrated smooth cytoskeletal labelling in control (B)
neurons, which became punctate and disassociated following Cu(II)Ab1–40 treatment (C). Treatment with 20mMZ n 7MT-2A prevented Ab-induced
structural changes in the neuronal cytoskeleton (D). Scale bar=25mm.
doi:10.1371/journal.pone.0012030.g003
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copper-mediated Ab aggregation (both Ab1–40 and Ab1–42), and
that this involves a specific metal exchange interaction. Hence,
Zn7MT-2A (but not Cu10MT-2A or CaMeMT-2A) prevents
soluble Cu(II)-Ab1–40 from forming SDS-insoluble Ab1–40
aggregates. This observation might be explained by the well-
characterised ability of higher binding affinity metals (ie: copper)
to displace lower affinity metals (ie: zinc) within MT [for review
see 33]. Similarly, published reports indicate that Ab has a
Cu(II) binding affinity of between 10
26 to 10
211 [34,35], while
MT-2A has been reported to have a binding affinity for Cu(II)
of 10
219 [36]. This supports the proposition that MT-2A is
capable of removing Cu(II) ions from Cu(II)-Ab.I n t e r e s t i n g l y ,
we found that apo-MT-2A (metal free MT-2A) was unable to
prevent soluble Cu(II)-Ab from forming SDS-insoluble Ab
aggregates. Apo-MT-2A has a high affinity for free copper
initially suggesting that it might be able to extract Cu from Ab
aggregates. It is possible that the apo-MT rapidly becomes
oxidised (via disulphide-bond formation between cysteine
residues), which would prevent apo-MT from binding to metals.
Or it might be that the ability of MT to participate in an inter-
molecular interaction with Ab under biological conditions is
dependent on not just the relative copper binding affinity
between the two proteins, but also on the tertiary structure of
the zinc-metallated form of metallothionein, which is funda-
mentally different to the uncoordinated structure found in the
apo-thionein. Finally, ICP-MS demonstrated that there was
almost 40% less copper in the pellet fraction when Cu(II)-Ab
was aggregated in the presence of Zn7MT-2A. In summary, we
p r o v i d es t r o n ge v i d e n c et h a tam e t a le x c h a n g eb e t w e e nC u ( I I ) -
Ab and Zn7MT-2A is responsible for blocking the aggregation
of Ab into an insoluble form.
Figure 4. A 40mM Cu(II)-Ab1–40 solution was separated on a PD MidiTrap
TM G-25 column, and the protein (A280) and metal (ICP-MS)
content of each fraction determined (A). Only those fractions containing Ab peptide also contained copper (A), indicating that the Cu(II)-Ab1–40
solution did not contain any free copper ions. The neurotoxicity of all fractions was subsequently tested, and only those containing Cu(II)-Ab1–40
exhibited neurotoxic activity (B). E – eluate, F – collected fraction.
doi:10.1371/journal.pone.0012030.g004
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lower concentrations than Zn7MT-3 in preventing copper-
mediated Ab1–40 aggregation. We predict that this difference
might be related to the relative copper binding affinities of MT-2A
and MT-3, and based upon our experiments with chimeric MT
proteins we believe that the a-domain of MT-2A is particularly
Figure 6. A non-invasive microelectrode ionic flux measuring (MIFE) technique was used to measure the kinetics of K
+ and Ca
2+
fluxes simultaneously in response to Cu(II)-Ab and Zn7MT-2A. Treatment with 40mM Cu(II)Ab1–40 resulted in a massive efflux of K
+ out of
neurons (A), and Ca
2+ influx into neurons (B). Quantification of net ion flux revealed that co-treatment with Zn7MT-2A completely blocked Cu(II)Ab-
induced changes in K
+ (A and C) and Ca
2+ fluxes (B and D), at a concentration of .5mM. For all MIFE data, the sign convention is ‘‘influx positive’’.
Error bars represent standard error of the mean calculated from at least three different experiments. * - p,0.05 compared to Cu(II)-Ab treated cells
(One-Way ANOVA).
doi:10.1371/journal.pone.0012030.g006
Figure 5. Treatment with 20mMC u 10MT-2A or CaMeMT-2A had no protective effect against 40mMA b1–40 (in the presence of 40mM
CuCl2 and 300mM ascorbate) (A). Treatment of cortical neurons with 10mM or 100mMH 2O2 for two hours resulted in substantial neuronal death,
which was not prevented by co-treatment with 20mMZ n 7MT-2A (B). Error bars represent standard error of the mean calculated from at least three
experimental replicates. In panel A, * - p,0.05 compared to untreated cells (One-Way ANOVA). In panel B, Two-Way ANOVA analysis was performed,
and * - p,0.05 compared to untreated cells, # -p ,0.05 between treatments.
doi:10.1371/journal.pone.0012030.g005
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a- and b- domains of MT for copper means that the activity of
MT-2A and MT-3 towards copper-induced Ab aggregation will
probably depend on the molar ratio of MT to Ab. In this regard, it
is generally considered that the b-domain of MT fills with copper
first, followed by the a-domain. We show that MT-2A will prevent
aggregation of Cu(II)-Ab even at low relative levels of this isoform
(eg 0.5–5 mMM Tt o2 5mMA b), whereas MT-3 requires a higher
MT:Ab ratio (25 mMM Tt o2 5mMA b) for activity. This most
likely also explains the difference between MT-2A and MT-3 in
the neurotoxicity data, in which we used 40mM Cu(II)-Ab to
20mM MT. We predict that when the ratio of Ab to MT is
equimolar that it will be primarily the b-domains of MT that will
be filled with copper, and that in this scenario MT-2A and MT-3
will protect equally against Cu(II)-Ab neurotoxicity.
We also found that Zn7MT-2A protects neurons against Cu(II)-
Ab toxicity. We believe that this involves a zinc/copper metal-
exchange between Zn7MT-2A and Cu(II)-Ab that subsequently
prevents Ab-bound copper from participating in redox-reactions
and producing reactive oxygen species [as suggested in 23].
Hence, only Zn7MT-2A but not Cu10MT-2A or CaMeMT-2A
was capable of protecting cortical neurons from soluble Cu(II)-Ab
neurotoxicity. Notably, Cu10MT-2A itself was not toxic to
neurons, indicating that when copper is bound to MT (for
instance following metal-swap with Cu(II)-Ab) that it is unable to
produce ROS. As evidence that MT-2A is not acting downstream
by scavenging the H2O2 generated by Cu(II)-Ab, we found that
Zn7MT-2A provided only a small degree of protection against
direct H2O2 neurotoxicity. This suggests that Zn7MT-2A
neuroprotection against Cu(II)-Ab is primarily afforded through
a zinc/copper metal swap and subsequent inhibition of H2O2
generation. We do note that it is possible that when Cu(II)-Ab is
applied to neurons that some copper is released from the complex,
and that this free copper is also partly responsible for
neurotoxicity. Although, as noted by Meloni et al [23], we think
that only a small amount of copper is released from Cu(II)-Ab
upon addition into the culture medium and the primary cause of
neurotoxicity is the Cu(II)-Ab complex.
Finally, using a direct and sensitive technique, MIFE, to
measure the kinetics of ion fluxes, we were able to determine that
oxidative stress (H2O2) generated by soluble Cu(II)-Ab induces a
rapid net efflux of K
+ and mild net influx of Ca
2+ into cortical
neurons most likely via increased oxidative stress. Notably, K
+
efflux from cells is a well established trigger of apoptosis. These
observations are also in accordance with the results of other groups
who have demonstrated that H2O2 induces substantial dysregu-
lation in neuronal K
+ channel conductance [37] and calcium
homeostasis [38]. Importantly, we found that treatment with
Zn7MT-2A completely abolished the Cu(II)-Ab-induced changes
in K
+ and Ca
2+ net ion fluxes. Taken together, our data suggests
that the neuroprotective actions of MT-2A lie in its ability to
exchange metals with Cu(II)-Ab to stop production of ROS, and
preventing subsequent detrimental changes in ionic balance within
neurons.
We believe that our results may reflect a physiological action of
MT-2A in the Alzheimer’s brain. For instance, MT-1/2 levels in
the adult human brain have been reported to be approximately
40mg/g [39]. Expression is primarily by astrocytes, with very low
levels of MT-2A expressed in neurons. We have recently reported
that secretion of MT-2A by cultured astrocytes can be induced
under certain physiological conditions and that extracellular MT-
2A can be detected in the site of a physical injury to the brain [15].
Hence, it is conceivable that under stressful situations MT-2A may
be secreted from astrocytes into the synaptic vicinity and reach the
levels that we have demonstrated are capable of modulating Cu-
mediated Ab aggregation.
Because of the considerable published data linking metal-
binding to the aggregation of Ab, metal-chelation drugs have been
proposed as a potential therapy for AD [40,41]. An excellent
example of this approach is the administration of the copper- and
zinc- chelating drug clioquinol, which has been reported to
prevent plaque formation in transgenic AD mice [42]. The use of
such metal-chelating drugs might not only reduce metal-mediated
aggregation of Ab, but also limit the formation of Cu(II)-Ab and
thus prevent the generation of oxidative stress and subsequent
neurotoxicity. One criticism of metal-chelation therapies for AD is
that these chelating agents remove metal from Ab leaving a metal-
free Ab that could feasibly readily bind metals again. Hence, more
recently, metal redistribution has been proposed as a more
appropriate goal of metal-targeted strategies for AD [41]. In this
regard, we believe that MT-2A might represent a possible
candidate as a metal-redistribution therapeutic agent, as the metal
exchange between MT and Ab leaves the Ab in a Zn-bound non-
toxic form, and redistributes copper into an inert Cu-MT form.
In summary we provide compelling evidence that MT-2A can
protect against copper-induced Ab aggregation and neurotoxicity.
This action of MT-2A appears to involve a metal-swap between
Zn7MT-2A and Cu(II)-Ab ˜ Furthermore .. MT-2A can block Cu(II)-
Ab induced changes in ion homeostasis and neurotoxicity of
cultured cortical neurons. We propose that there is therapeutic
potential in a MT-2A based approach to reducing Ab deposition
in AD.
Methods
Metallothionein protein
MT proteins were provided by Bestenbalt LLC (Estonia) as
.98% pure HPLC-purified proteins. For this study we have used
Zn7MT-2A, Zn7MT-3, and different metallated forms of MT-2A
including Cu10MT-2A and carboxymethylated MT-2A (Ca-
MeMT-2A). All MT proteins were provided directly from
Bestenbalt in lyophilised form in either a metal free (apo), or in
Zn7MT or C10MT state, Metallation of MT-2A was prepared as
we have described previously for Zn7MT-3 [43]. Briefly, the
protein was dissolved in 20 mM Tris-HCl, pH 8 and the pH was
lowered to 2.5. Ten equivalents of Zn
2+ or 12 equivalents of Cu
+
was added and the pH raised to 8. The buffer was exchanged to
10 mM ammonium bicarbonate, and the solution frozen at
280uC and freeze dried. The lyophilised proteins were reconsti-
tuted in Milli-Q water (pH 7.4) immediately prior to use.
In vitro copper-mediated Ab aggregation assay
Synthetic monomeric Ab1–40 and Ab1–42 were purchased from
EZBiolab (US). The dried Ab peptide contains trifluoroacetate
(TFA) as a counterion, and in analysis it was found that the
synthetic Ab used in this study contained approximately 5–10%
TFA. For in vitro Ab aggregation studies, purified Ab1–40 and
Ab1–42 (EZBiolab) was dissolved in Tris buffer (20mM Tris-HCl,
100mM NaCl, pH 7.4) to give a 25mM solution, followed by
addition of an equimolar concentration of CuCl2 and 200mM
ascorbate. The solution was incubated at 37uC for 72hrs with
shaking (300 rpm). Ab aggregation was assessed by gel electro-
phoresis. Briefly, aggregates were collected by ultracentrifugation
at 20,000G for 1 hour then resuspended in LDS (lithium dodecyl
sulfate) sample buffer (Invitrogen) and electrophoresed under
reducing conditions (b-mercaptoethanol in sample and Invitrogen
anti-oxidant supplement in the running buffer) on a 10% Nu-Page
Bis-Tris gel (Invitrogen) at 200V for 30 minutes. Protein bands
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were assessed as SDS-soluble when the Ab protein was observed in
monomeric form on the gel and as SDS-insoluble when not
observed on the gel.
Electrospray ionisation mass spectrometry (ESI-MS) metal
binding analysis
Copper binding affinity of MT-3 was determined in strictly
similar conditions and by identical approach, which we have
recently elaborated for MT-2A [24]. Briefly, 3.3 mM samples of
apo-MT-3 were reconstituted with Cu(I) by addition of 12
equivalents of Cu(I)DTT complex in 20 mM ammonium acetate
pH 7.5 in the presence of 10 mM DTT. After addition of various
concentrations of Cu(I)-chelating reagent diethyl dithio carbamate
(DETC), samples were incubated for 2 minutes and injected into
the electrospray ion source of QSTAR Elite ESI-Q-TOF MS
instrument (Applied Biosystems, Foster City, USA) by a syringe
pump at 6 ml/min and ESI-MS spectra were recorded over a
5 minute period in m/Z region from 500–3000 Da at following
instrument parameters: ion spray voltage 5500 V; source gas 45 l/
min; curtain gas 20 l/min; declustering potential 60V; focusing
potential 320 V; detector voltage 2300V.
The Cu-binding affinity of MT-3 was determined from ESI-MS
titration results of Cu12MT-3 with DETC by correlating the
fractional occupancy of Cu(I)-binding sites in MT-3 with the
concentration of free Cu(I) ions. The fractional occupancy of
Cu(I)-binding sites in MT-3 (Y) was calculated from ESI-MS
spectra (considering that there are 12 Cu(I) binding sites in MT-3)
by using the following equation:
Y~
X 12
0
nICunMT{3=12|
X 12
0
ICunMT{3 ð1Þ
where ICunMT-3 denotes the intensity of the CunMT-3 peak in the
ESI-MS spectra. The fractional occupancy of Cu(I) binding sites in
MT-3 was correlated with the concentration of free Cu(I) ions in
the sample calculated using the apparent dissociation constant for
DETC that we have recently determined using the same
techniques (KCu=13.8 fM) [24]. The obtained binding curve for
MT-3, presented in Fig. 2C, was fitted nonlinearly with the Hill
equation (equation 2) and also linearly to the linear version of the
Hill equation with the program ‘‘Origin 6.1’’ (OriginLab
Corporation, USA).
Y~
Cu(I) ½ 
n
KCu
nz Cu(I) ½ 
n ð2Þ
The nonlinear fitting presented in Fig. 2C yielded KCu values of
0.4760.01 fM and n values of 1.2560.06 and n=1.34 was
obtained in linear fitting mode. KCu is equal to the concentration
of free Cu(I) ions at half saturation of MT-3 with Cu(I) ions,
reflecting the apparent average affinity of MT-3 towards Cu(I)
ions, which is similar to that for MT-2 KCu values of
0.4160.02 fM [24]. A Hill coefficient close to 1 indicates that
there exists only weak apparent positive cooperativity in the
binding of Cu(I) ions to MT-3, whereas strong positive
cooperativity (n=3.3) exists in case of MT-2, which is demetal-
lated in very narrow range of free Cu(I) ions [24]. As seen from
Fig. 2B there are two metal-thiolate clusters in Cu12MT-3, both
composed from 6 Cu(I) ions. The first hexacopper-thiolate cluster
dissociates readily in the presence of 0.5 mM DETC, whereas
DETC can not dissociate copper from Cu10MT-2 even at 1 mM
concentration [24]. The second hexacopper-thiolate cluster of
MT-3 is half desaturated at 3 mM DETC, which is similar to the
behaviour of hexacopper-thiolate cluster in MT-2 [24].
Inductively coupled plasma mass spectrometry (ICP-MS)
metal content analysis
In some cases, the Ab aggregation pellet and supernatant
fractions were collected post-ultracentrifugation and their metal
content determined by Inductively Coupled Plasma Mass
Spectrometry (ICP-MS). Prior to analysis samples were further
diluted 106with ultra-pure water (.18 MOhm) with nitric acid
and Indium (as an internal standard) addition to final concentra-
tions 1% and 100 ppb, respectively. Analysis was undertaken using
an ELEMENT High Resolution ICP-MS operating in medium
resolution mode, enabling
63Cu and
66Zn isotopes to be monitored
free from overlapping spectral interferences. Both elements were
quantified using external calibration methodology, with blank
subtraction. Typical analytical protocols have been presented
previously [44].
Rodent cortical neural cell cultures
All animal procedures were performed in accordance with the
animal ethics guidelines of the University of Tasmania Animal
Ethics Committee. Neural cultures were prepared as reported
previously [45], and briefly involved the removal of cortices from
embryonic day 17 Hooded Wistar embryos, which were incubated
with 0.1% trypsin in HEPES buffer at 37uC for 20 minutes. After
three washes with warmed HEPES, the tissue was triturated and
plated at 5610
4 cells per coverslip onto 13mm
2 glass coverslips in
Neurobasal medium (Gibco) and maintained at 37uCi n
humidified air containing 5% CO2.
Rat cortical neuron toxicity assay
To induce cortical neuron toxicity, 40mM soluble Ab1–40 was
applied to neurons in the presence of 40mMC u C l 2 and 300mM
ascorbate. Under these specific conditions, it has been demonstrated
that all free copper is rapidly bound by Ab1–40 [23]. The presence of
physiological levels of ascorbate permits cycling between copper (II)
and (I) oxidation states, as occurs within cellular environments
allowing copper to bind to proteins in either Cu(I) or Cu(II) oxidation
states. After 24 hours, neuronal viability was measured by the degree
of cellular metabolic reduction of alamarBlueH, determined by
fluorescence (excitation 535nm, emission 595nm), and was expressed
as the percentage of the signal obtained from the vehicle-treated
culture. Ab1–40 was used in this study because there is a wider
differential in the relative toxicity of copper vs zinc forms of Ab1–40
compared to Ab1–42 (ie: only Cu-Ab1–40 and not Zn-Ab1–40 is
neurotoxic, while both Cu- and Zn-Ab1–42 are neurotoxic). Using
Ab1–40 thus maximises the effect of the hypothesised metal swap
between ZnMT-2A and Cu-Ab1–40, and removes the additional but
complicating possibility that metallothionein can independently
protect against Zn-Ab1–42 toxicity.
Statistical analyses of tissue culture experiments
For each experiment unless otherwise stated, a minimum of four
wells from at least three separate cultures (derived from different
animals), were used for quantification, blinded to conditions.
Statistical analysis was completed using SPSS 16.0 (SPSS). When
data was unequally distributed, data was transformed so that the
residuals were approximately normally distributed. Statistical
significance was calculated using One-Way and Two-Way
ANOVA with Tukey’s Post Hoc Test. All graphical data is
presented as mean 6 SEM, significance p,0.05.
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The theory of non-invasive microelectrode ion flux (MIFE)
measurements was reviewed recently [45] and the complete
experimental procedure including ion-selective microelectrode
fabrication and cell preparation and immobilisation are given
elsewhere [46,47]. Cortical neurons for the MIFE measurements
were grown for three days at a 1610
5 cells/well on poly-L-lysine
cover slips as described above. By day three a dense monolayer of
neurons had developed. Cells were washed in and adapted to the
MIFE artificial CSF (aCSF) for one hour prior to experiments.
The composition of the aCSF was: 150mM NaCl, 0.5mM KCl,
0.5mM CaCl2, 1.5mM MgCl2, 1.25mM NaH2PO4, 5mM NaH-
CO3, 25mM glucose, pH 7.2. Data was acquired at a rate of 15
samples/sec and later averaged over 10 second intervals. Each
experiment was repeated upon at least four different coverslips
from three different neuronal cultures.
Supporting Information
Figure S1 Direct cell counting revealed that treatment of 3DIV
rat cortical neuron cultures with 40mM Cu(II)Ab1–40 resulted in
significant neuronal death, which could be blocked by the co-
addition of 20mM of Zn7MT-2A. Error bars represent standard
error of the mean calculated from at least three different
experiments. * - p,0.05 (One-Way ANOVA).
Found at: doi:10.1371/journal.pone.0012030.s001 (3.21 MB TIF)
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